Poster-Quality of Life and Outcomes
October 25, 2021
Multiple Sclerosis: The Relationship of Cognitive Impairment and Self-Efficacy of Medication Management
Background: Multiple Sclerosis (MS) is a chronic disease for which there are multiple disease modifying therapies and symptomatic...
Poster-Disease-modifying Therapy
October 25, 2021
Opportunities and Pitfalls in the Assessment of Brain Atrophy in Dimethyl Fumarate-Treated Relapsing Multiple Sclerosis Patients Using Real-World Data
Background: The majority of real-world data (RWD) on disease-modifying treatments (DMTs) for multiple sclerosis (MS) is based on clinical...
Poster-Case Reports / Case Series
October 25, 2021
Case Report of a Severe Cutaneous Lupus Erythematosus Flare in a Patient Treated with Eculizumab for the Treatment of Neuromyeltis Optica Spectrum Disorder
Background:: Eculizumab is a long-acting humanized monoclonal antibody targeted against complement C5. By preventing the cleavage of C5...
Poster-Disease-modifying Therapy
October 25, 2021
Recently Diagnosed Treatment-Naive RRMS: 1-Year Safety Data from the Ocrelizumab Phase IIIb ENSEMBLE Study
Background: ENSEMBLE (NCT03085810) is a multicenter, open-label, single-arm Phase IIIb study evaluating the effectiveness and safety of...